Unsere Stellenangebote in der Pflege!

Klinische Studien

Die Klinik für Innere Medizin 1 ist überregional vernetzt und Mitglied in den führenden Studiengruppen zur Behandlung von onkologischen Erkrankungen wie

  • der German Lymphoma Alliance (GLA),
  • der Acute Myeloid Leukemia Study Group (AMLSG),
  • der Studien-Allianz Leukämie (SAL)
  • der German Hodgkin Study Group (GHSG)
  • der GMALL
  • der German Multicenter Study Group on Adult Acute Lymphoblastic Leukemia (GMALL)
  • der Deutschen CLL-Studiengruppe (DCLLSG)
  • der Deutschen Studiengruppe Multiples Myelom (DSMM) GMMG
  • der Arbeitsgemeinschaft internistische Onkologie (AIO)

Darüber hinaus ist Prof. Dr. med. Gerhard Held Mitglied der Steuerungsgruppe der AWMF und Cochrane-Gruppe: S3 Leitlinie Diagnostik, Therapie und Nachsorge für erwachsene Patienten mit einem diffusen großzelligen B-Zell-Lymphom.

Rekrutierende Studien und Register

Rektumkarzinom:

ACO-ARO-AIO 18.2, EudraCT: 2018-001356-35
Preoperative FOLFOX versus postoperative risk-adapted chemotherapy in patients with locally advanced rectal cancer and low risk for local failure: A randomized phase III trial of the German Rectal Cancer Study Group

Weitere Informationen gibt es hier

Akute myeloische Leukämie:

AMLSG 30-18, EudraCT-Nr.: 2018-002678-34
Randomized Phase III Study of Standard Intensive Chemotherapy versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics

Mehr Informationen gibt es hier

AMLSG 28-18/HOVON 156 AML, EudraCT Nr.:2018-000624-33
A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one-year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy

Mehr Informationen gibt es hier

AMLSG 29-18/HOVON 150 AML, EudraCT Nr.: 2018-000451-41
A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolodation therapy followed by Maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy.

Mehr Informationen gibt es hier

AMLSG-BiO-Register, Universitätsklinik Ulm

Mehr Informationen gibt es hier

AML-Register der Studienallianz Leukämie (SAL), Technische Universität Dresden

Mehr Informationen gibt es hier

Akute promyelozyten Leukämie:

TUD-APOLLO-064, EudraCT: 2015-001151-68
A randomized Phase III study to compare arsenic trioxide (ATO) combined to ATRA and idarubicin versus standard ATRA and anthracycline-based chemotherapy (AIDA regimen) for patients with newly diagnosed, high-risk acute promyelocytic leukemia

Rekrutierung endet am: 31. Juli 22

NAPOLEON-Register
Nationale APL Beobachtungsstudie der SAL, AMLCG u. der AMLSG

Mehr Informationen gibt es hier

Akute lymphatische Leukämie:

GMALL-Register der Johann Wolfgang-Goethe-Universität Frankfurt

Mehr Informationen gibt es hier

Chronische lymphatische Leukämie:

CLL17, EudraCT Nr. 2019-003854-99
A phase 3 multicenter, randomized, prospective, open-label trial of ibrutinib monotherapy versus fixed-duration venetoclax plus obinutuzumab versus fixed-duration ibrutinib plus venetoclax in patients with previously untreated chronic lymphocytic leukemia

Mehr Informationen gibt es hier

Hodgkin Lymphom:

HD21, EudraCT: 2014-005130-55
Elderly Kohorte (61 bis 75 Jahre)
Therapieoptimierungsstudie in der Primärtherapie des fortgeschrittenen Hodgkin Lymphoms. Vergleich 6 Zyklen BEACOPPesk mit 6 Zyklen BrECADD

Mehr Informationen gibt es hier

Non-Hodgkin Lymphom:

COPA-R-CHOP, EudraCT: 2018-003560
A prospective multicenter phase 2 study of copanlisib in combination with rituximab and CHOP chemotherapy (COPA-R-CHOP) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL)

Mehr Informationen gibt es hier

DSHNHL 2015-1 (NIVEAU-Studie), EudraCT: 2016-002272-27
Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive NHL in first Relapse or Progression by adding Nivolumab to Gemcitabine, Oxaliplatin plus Rituximab in case of CD20+ Disease

Mehr Informationen gibt es hier

Pola-R-ICE/GLA 2017-R2, EudraCT-Nr. 2019-002962-10
An open-label, prospective Phase III clinical study to compare polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) with rituximab, ifosfamide, carboplatin and etoposide (R-ICE) alone as salvage therapy in patients with primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL)

Mehr Informationen gibt es hier

Lungenkarzinom:

FINN: Eine deutschlandweite, prospektive, multizentrische Beobachtungsstudie der Erstlininientherapie mit Nivolumab und Ipilimumab in Kombination mit zwei Zyklen Chemotherapie bei Patienten mit metastasiertem nicht-kleinzelligem Lungenkarzinom
Sponsor: Bristol-Meyers-Squibb

Mehr Informationen gibt es hier

Mammakarzinom:

GBG 93 Padma, EudraCT-Nr.: 2016-004482-89
Eine randomisierte, offene, multizentrische Phase IV Studie zur Evaluierung von Palbociclib und endokriner Therapie im Vergleich zu einer Chemotherapie-basierten Behandlungsstrategie bei Patienten mit Hormonrezeptor-positivem / HER2-negativem, metastasierten Brustkrebs in der Real-World-Situation.

Mehr Informationen gibt es hier

Follikuläres Lymphom:

Celestimo GO42909 EudraCT Nr. 2020-005239-53
Phase III randomized, open-label, multicenter study evaluating efficacy and safety of mosunetuzumab in combination with lenalidomide in comparison to rituximab in combination with lenalidomide in patients with follicular lymphoma after at least one line of systemic therapy

Mehr Informationen gibt es hier

Vorträge auf nationalen und internationalen Kongressen

  • 2022 European Society Radiation Oncology – ESTRO Congress Copenhagen: All the hassle with haematopoietic systems. Zum Programm
  • 2021 Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie: V456 - Nivolumab in Kombination mit Gemcitabine und Oxaliplatin (GemOx) bei rezidivierten/refraktären T-Zell Lymphomen: vorläufige Ergebnisse des experimentellen Arms der Niveau Studie / Nivolumab in combination with Gemcitabine and Oxaliplatin (GemOx) in Relapse/Refractory T-cell Lymphoma: Preliminary results of the experimental arm of the NIVEAU trial. Zum Vortrag
  • 2020 European Hematology Association Congress: Role of Radiotherapy and Dose-Densification of R-CHOP in PrimaryMediastinal B-Cell Lymphoma: A Subgroup Analysis of the UNFOLDER Trial of the German Lymphoma Alliance (GLA). Zum Vortrag
  • 2018 Annual Meeting of the American Society of Hematology: Excellent outcome of young patients (18-60 years) with favourable-prognosis diffuse large B cell lymphoma (DLBCL) treated with 4 cycles CHOP plus 6 applications of rituximab: Results of the 592 patients of the FLYER trial of the DSHNHL/GLA. Zum Vortrag
  • 2018 Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie: Welches Studiendesign benötigen wir um Fortschritte bei der Therapie von DLBCL-Patienten zu erzielen? Zum Vortrag

Publikationsverzeichnis von Prof. Dr. med. Gerhard Held

Die fünf wichtigsten Publikationen

  • Poeschel, V., G. Held, M. Ziepert, M. Witzens-Harig, H. Holte, L. Thurner, P. Borchmann, A. Viardot, M. Soekler, U. Keller, C. Schmidt, L. Truemper, R. Mahlberg, R. Marks, H.-G. Hoeffkes, B. Metzner, J. Dierlamm, N. Frickhofen, M. Haenel, A. Neubauer, M. Kneba, F. Merli, A. Tucci, P. de Nully Brown, M. Federico, E. Lengfelder, A. di Rocco, R. Trappe, A. Rosenwald, C. Berdel, M. Maisenhoelder, O. Shpilberg, J. Amam, K. Christofyllakis, F. Hartmann, N. Murawski, S. Stilgenbauer, M. Nickelsen, G. Wulf, B. Glass, N. Schmitz, B. Altmann, M. Loeffler and M. Pfreundschuh (2019). "Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial." The Lancet 394(10216): 2271-2281.
  • Held, G., I. F. Luescher, F. Neumann, C. Papaioannou, T. Schirrmann, M. Sester, S. Smola and M. Pfreundschuh (2015). "MHC/Peptide-Specific Interaction of the Humoral Immune System: A New Category of Antibodies." J Immunol 195(9): 4210-4217.
  • Held, G., N. Murawski, M. Ziepert, J. Fleckenstein, V. Poschel, C. Zwick, J. Bittenbring, M. Hanel, S. Wilhelm, J. Schubert, N. Schmitz, M. Loffler, C. Rube and M. Pfreundschuh (2014). "Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma." Journal of clinical oncology: official journal of the American Society of Clinical Oncology 32(11): 1112-1118.
  • Held, G., S. Zeynalova, N. Murawski, M. Ziepert, B. Kempf, A. Viardot, M. Dreyling, M. Hallek, M. Witzens-Harig, J. Fleckenstein, C. Rube, C. Zwick, B. Glass, N. Schmitz and M. Pfreundschuh (2013). "Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement." Journal of clinical oncology: official journal of the American Society of Clinical Oncology 31(32): 4115-4122.
  • Held, G., A. Wadle, N. Dauth, G. Stewart-Jones, C. Sturm, M. Thiel, C. Zwick, D. Dieckmann, G. Schuler, H. R. Hoogenboom, F. Levy, V. Cerundolo, M. Pfreundschuh and C. Renner (2007). "MHC-peptide-specific antibodies reveal inefficient presentation of an HLA-A*0201-restricted, Melan-A-derived peptide after active intracellular processing." European journal of immunology 37(7): 2008-2017.

2022

  • Houot, R., V. Poeschel, B. Altmann, S. Angel, L. Thurner, T. Illmer, M. Andre, M. Dreyling, H. Maisonneuve, H. Tilly, S. Mayer, O. Casasnovas, S. Le Gouill, F. Offner, G. Cartron, A. Kerkhoff, T. Weber, J. Hoffmann, M. Ziepert, W. Klapper, E. Itti, D. Hellwig, G. Natchkebia, L. de Leval, A. Rosenwald, C. Haioun, L. Dercle, P. Gaulard and G. Held (2022). "Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma." HemaSphere 6(2): e672.
  • Kaddu-Mulindwa, D., B. Altmann, S. Robrecht, M. Ziepert, E. Regitz, E. Tausch, G. Held, V. Poeschel, V. Lesan, J. T. Bittenbring, L. Thurner, M. Pfreundschuh, K. Christofyllakis, L. Truemper, M. Loeffler, N. Schmitz, M. Hoth, M. Hallek, K. Fischer, S. Stilgenbauer, M. Bewarder and T. M. Rixecker (2022). "KIR2DS1-HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials." Lancet Haematol 9(2): e133-e142.
  • Kaddu-Mulindwa, D., P. Gödel, N. Kutsch, J. M. Heger, C. Scheid, P. Borchmann, U. Holtick, G. Held, L. Thurner, M. Bewarder, T. Rixecker and J. T. Bittenbring (2022). "Salvage High-dose Melphalan With Autologous Stem cell Transplantation as Bridge to Consolidation Therapy for Chemoresistant Aggressive B-cell Lymphoma." Clin Lymphoma Myeloma Leuk.
  • Kaddu-Mulindwa, D., V. Lesan, C. Berdel, S. Stilgenbauer, M. Bewarder, L. Thurner, M. Witzens-Harig, A. Viardot, M. Soekler, U. Keller, L. Truemper, K. Christofyllakis, O. Fleser, J. T. Bittenbring, V. Poeschel, G. Held and P. Jagoda (2022). "Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trial." Leuk Lymphoma 63(2): 326-334.

2021

  • Croci, G. A., R. K. H. Au-Yeung, S. Reinke, A. M. Staiger, K. Koch, I. Oschlies, J. Richter, V. Poeschel, G. Held, M. Loeffler, L. Trümper, A. Rosenwald, G. Ott, R. Spang, B. Altmann, M. Ziepert and W. Klapper (2021). "SPARC-positive macrophages are the superior prognostic factor in the microenvironment of diffuse large B-cell lymphoma and independent of MYC rearrangement and double-/triple-hit status." Ann Oncol 32(11): 1400-1409
  • Frontzek, F., M. Ziepert, M. Nickelsen, B. Altmann, B. Glass, M. Haenel, L. Truemper, G. Held, M. Bentz, P. Borchmann, M. Dreyling, A. Viardot, F. P. Kroschinsky, B. Metzner, A. M. Staiger, H. Horn, G. Ott, A. Rosenwald, M. Loeffler, G. Lenz and N. Schmitz (2021). "Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial." Lancet Haematol 8(4): e267-e277.
  • Kaddu-Mulindwa, D., B. Altmann, G. Held, S. Angel, S. Stilgenbauer, L. Thurner, M. Bewarder, M. Schwier, M. Pfreundschuh, M. Löffler, K. Menhart, J. Grosse, M. Ziepert, K. Herrmann, U. Dührsen, A. Hüttmann, F. Barbato, V. Poeschel and D. Hellwig (2021). "FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials." European Journal of Nuclear Medicine and Molecular Imaging.
  • Kaddu-Mulindwa, D., V. Lesan, C. Berdel, S. Stilgenbauer, M. Bewarder, L. Thurner, M. Witzens-Harig, A. Viardot, M. Soekler, U. Keller, L. Truemper, K. Christofyllakis, O. Fleser, J. T. Bittenbring, V. Poeschel, G. Held and P. Jagoda (2021). "Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trial." Leukemia & Lymphoma: 1-9.
  • Kaddu-Mulindwa, D., M. Rosolowski, M. Ziepert, E. Regitz, G. Assmann, M. Bewarder, G. Held, M. Pfreundschuh and J. T. Bittenbring (2021). "VEGFR2 and VEGFA polymorphisms are not associated with an inferior prognosis in Caucasian patients with aggressive B-cell lymphoma." Eur J Haematol 106(1): 100-104.
  • Nordmo, C., G. Glehr, M. Altenbuchinger, R. Spang, M. Ziepert, H. Horn, A. M. Staiger, G. Ott, N. Schmitz, G. Held, H. Einsele, M. Topp, A. Rosenwald and H. Rauert-Wunderlich (2021). "Identification of a miRNA based model to detect prognostic subgroups in patients with aggressive B-cell lymphoma." Leuk Lymphoma 62(5): 1107-1115.
  • Thurner, L., S. Hartmann, M. Bewarder, N. Fadle, E. Regitz, C. Schormann, N. Quiroga, M. Kemele, W. Klapper, A. Rosenwald, L. Trümper, R. M. Bohle, A. Nimmesgern, C. Körbel, M. W. Lascke, M. D. Menger, S. Barth, B. Kubuschok, A. Mottok, D. Kaddu-Mulindwa, M. L. Hansmann, V. Pöschel, G. Held, N. Murawski, S. Stilgenbauer, F. Neumann, K. D. Preuss and M. Pfreundschuh (2021). "Identification of the atypically modified autoantigen Ars2 as the target of B-cell receptors from activated B-cell-type diffuse large B-cell lymphoma." Haematologica 106(8): 2224-2232.
  • Wulf, G. G., B. Altmann, M. Ziepert, F. D'Amore, G. Held, R. Greil, O. Tournilhac, T. Relander, A. Viardot, M. Wilhelm, C. Wilhelm, A. Pezzutto, J. M. Zijlstra, E. V. D. Neste, P. J. Lugtenburg, J. K. Doorduijn, M. V. Gelder, G. W. van Imhoff, F. Zettl, F. Braulke, M. Nickelsen, B. Glass, A. Rosenwald, P. Gaulard, M. Loeffler, M. Pfreundschuh, N. Schmitz and L. Trümper (2021). "Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial." Leukemia 35(1): 143-155.
  • Zettl, F., M. Ziepert, B. Altmann, S. Zeynalova, G. Held, V. Pöschel, K. Hohloch, G. G. Wulf, B. Glass, N. Schmitz, M. Loeffler and L. Trümper (2021). "Age-dependent increase of treatment-related mortality in older patients with aggressive B cell lymphoma: analysis of outcome, treatment feasibility, and toxicity in 1171 elderly patients with aggressive B cell lymphoma-data from phase II and III trials of the DSHNHL (German High-Grade Non-Hodgkin's Lymphoma Study Group)." Ann Hematol 100(4): 1031-1038.

2020

  • Bewarder, M., G. Held, L. Thurner, S. Stilgenbauer, S. Smola, K. D. Preuss, G. Carbon, B. Bette, K. Christofyllakis, J. T. Bittenbring, A. Felbel, A. Hasse, N. Murawski, D. Kaddu-Mulindwa and F. Neumann (2020). "Characterization of an HLA-restricted and human cytomegalovirus-specific antibody repertoire with therapeutic potential." Cancer Immunol Immunother 69(8): 1535-1548.
  • Staiger, A. M., M. Altenbuchinger, M. Ziepert, C. Kohler, H. Horn, M. Huttner, K. S. Hüttl, G. Glehr, W. Klapper, M. Szczepanowski, J. Richter, H. Stein, A. C. Feller, P. Möller, M.-L. Hansmann, V. Poeschel, G. Held, M. Loeffler, N. Schmitz, L. Trümper, T. Pukrop, A. Rosenwald, G. Ott, R. Spang, M. Loeffler, R. Siebert, W. Klapper, R. Spang, L. Trümper, M. Pfreundschuh, N. Schmitz, L. Trümper, M. Loeffler, P. the Emed Demonstrator and G. German High Grade Non-Hodgkin’s Lymphoma Study (2020). "A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL." Leukemia 34(2): 543-552.
  • Ziepert, M., S. Lazzi, R. Santi, F. Vergoni, M. Granai, V. Mancini, A. Staiger, H. Horn, M. Löffler, V. Pöschel, G. Held, G. Wulf, L. H. Trümper, N. Schmitz, A. Rosenwald, E. Sabattini, K. N. Naresh, H. Stein, G. Ott and L. Leoncini (2020). "A 70% cut-off for MYC protein expression in diffuse large B cell lymphoma identifies a high-risk group of patients." Haematologica: haematol.2019.235556.

2019

  • Held, G. and B. Glass (2019). "Diffuses großzelliges B-Zell-Lymphom: Primär- und Rezidivtherapie." Der Onkologe 10: 880-891.
  • Poeschel, V., G. Held, M. Ziepert, M. Witzens-Harig, H. Holte, L. Thurner, P. Borchmann, A. Viardot, M. Soekler, U. Keller, C. Schmidt, L. Truemper, R. Mahlberg, R. Marks, H.-G. Hoeffkes, B. Metzner, J. Dierlamm, N. Frickhofen, M. Haenel, A. Neubauer, M. Kneba, F. Merli, A. Tucci, P. de Nully Brown, M. Federico, E. Lengfelder, A. di Rocco, R. Trappe, A. Rosenwald, C. Berdel, M. Maisenhoelder, O. Shpilberg, J. Amam, K. Christofyllakis, F. Hartmann, N. Murawski, S. Stilgenbauer, M. Nickelsen, G. Wulf, B. Glass, N. Schmitz, B. Altmann, M. Loeffler and M. Pfreundschuh (2019). "Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial." The Lancet 394(10216): 2271-2281.
  • Schlenk, R. F., D. Weber, W. Fiedler, H. R. Salih, G. Wulf, H. Salwender, T. Schroeder, T. Kindler, M. Lübbert, D. Wolf, J. Westermann, D. Kraemer, K. S. Götze, H.-A. Horst, J. Krauter, M. Girschikofsky, M. Ringhoffer, T. Südhoff, G. Held, H.-G. Derigs, R. Schroers, R. Greil, M. Grießhammer, E. Lange, A. Burchardt, U. Martens, B. Hertenstein, L. Marretta, M. Heuser, F. Thol, V. I. Gaidzik, W. Herr, J. Krzykalla, A. Benner, K. Döhner, A. Ganser, P. Paschka, H. Döhner and o. b. o. t. G.-A. A. S. Group (2019). "Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD." Blood 133(8): 840-851.
  • Wulf, G., J. Hasenkamp, W. Jung, C. Wilhelm, G. Held, M. Nickelsen, A. Leha, M. Pfreundschuh, N. Schmitz, L. Trümper and B. Glass (2019). "Allogeneic stem cell transplantation for patients with relapsed or refractory T-cell lymphoma: efficacy of lymphoma-directed conditioning against advanced disease." Bone Marrow Transplantation 54(6): 877-884.

2018

  • Avivi, I., L. Arcaini, V. V. Ferretti, A. Boumendil, H. Finel, G. Milone, F. Zaja, D. Liliana, M. Musso, B. Didier, E. Bachy, M. Wattad, E. Nicolas-Virelizier, M. Gramatzki, J.-H. Bourhis, D. Caillot, A. Haenel, G. Held, C. Thieblemont, P. Jindra, D. Pohlreich, F. Guilhot, F. Kroschinsky, B. Wahlin, C. Scheid, N. Ifrah, C. Berthou, P. Dreger, S. Montoto and A. Conconi (2018). "High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO." British Journal of Haematology 182(6): 807-815.
  • Gaidzik, V. I., D. Weber, P. Paschka, A. Kaumanns, S. Krieger, A. Corbacioglu, J. Krönke, S. Kapp-Schwoerer, D. Krämer, H. A. Horst, I. Schmidt-Wolf, G. Held, A. Kündgen, M. Ringhoffer, K. Götze, T. Kindler, W. Fiedler, M. Wattad, R. F. Schlenk, L. Bullinger, V. Teleanu, B. Schlegelberger, F. Thol, M. Heuser, A. Ganser, H. Döhner, K. Döhner and G. for the German-Austrian Acute Myeloid Leukemia Study (2018). "DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia." Leukemia 32(1): 30-37.

2017

  • Jahn, N., M. Agrawal, L. Bullinger, D. Weber, A. Corbacioglu, V. I. Gaidzik, L. Schmalbrock, F. Thol, M. Heuser, J. Krauter, G. Göhring, A. Kündgen, W. Fiedler, M. Wattad, G. Held, C. H. Köhne, H. A. Horst, M. Lübbert, A. Ganser, R. F. Schlenk, H. Döhner, K. Döhner and P. Paschka (2017). "Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): a study of the German-Austrian AML Study Group." Leukemia 31(4): 1012-1015.
  • Jaramillo, S., A. Benner, J. Krauter, H. Martin, T. Kindler, M. Bentz, H. R. Salih, G. Held, C. H. Köhne, K. Götze, M. Lübbert, A. Kündgen, P. Brossart, M. Wattad, H. Salwender, B. Hertenstein, D. Nachbaur, G. Wulf, H. A. Horst, H. Kirchen, W. Fiedler, A. Raghavachar, G. Russ, S. Kremers, E. Koller, V. Runde, G. Heil, D. Weber, G. Göhring, K. Döhner, A. Ganser, H. Döhner, R. F. Schlenk and G. for the German-Austrian Acute Myeloid Leukemia Study (2017). "Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia." Blood Cancer Journal 7(5): e564-e564.
  • Neuenhahn, M., J. Albrecht, M. Odendahl, F. Schlott, G. Dössinger, M. Schiemann, S. Lakshmipathi, K. Martin, D. Bunjes, S. Harsdorf, E. M. Weissinger, H. Menzel, M. Verbeek, L. Uharek, N. Kröger, E. Wagner, G. Kobbe, T. Schroeder, M. Schmitt, G. Held, W. Herr, L. Germeroth, H. Bonig, T. Tonn, H. Einsele, D. H. Busch and G. U. Grigoleit (2017). "Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT." Leukemia 31(10): 2161-2171.
  • Schlenk, R. F., P. Frech, D. Weber, P. Brossart, H. A. Horst, D. Kraemer, G. Held, M. Ringhoffer, A. Burchardt, G. Kobbe, K. Götze, D. Nachbaur, T. Fischer, M. Lübbert, H. R. Salih, H. Salwender, G. Wulf, E. Koller, M. Wattad, W. Fiedler, S. Kremers, H. Kirchen, B. Hertenstein, P. Paschka, V. I. Gaidzik, V. Teleanu, M. Heuser, F. Thol, K. Döhner, J. Krauter, A. Ganser, H. Döhner and A. and for the German-Austrian (2017). "Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia." Leukemia 31(5): 1217-1220.
  • Wattad, M., D. Weber, K. Döhner, J. Krauter, V. I. Gaidzik, P. Paschka, M. Heuser, F. Thol, T. Kindler, M. Lübbert, H. R. Salih, A. Kündgen, H. A. Horst, P. Brossart, K. Götze, D. Nachbaur, C. H. Köhne, M. Ringhoffer, G. Wulf, G. Held, H. Salwender, A. Benner, A. Ganser, H. Döhner, R. F. Schlenk and A. for the German-Austrian (2017). "Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure." Leukemia 31(6): 1306-1313.

2016

  • Gaidzik, V. I., V. Teleanu, E. Papaemmanuil, D. Weber, P. Paschka, J. Hahn, T. Wallrabenstein, B. Kolbinger, C. H. Köhne, H. A. Horst, P. Brossart, G. Held, A. Kündgen, M. Ringhoffer, K. Götze, M. Rummel, M. Gerstung, P. Campbell, J. M. Kraus, H. A. Kestler, F. Thol, M. Heuser, B. Schlegelberger, A. Ganser, L. Bullinger, R. F. Schlenk, K. Döhner, H. Döhner and G. for the German-Austrian Acute Myeloid Leukemia Study (2016). "Erratum: RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features." Leukemia 30(11): 2282-2282.
  • Gaidzik, V. I., V. Teleanu, E. Papaemmanuil, D. Weber, P. Paschka, J. Hahn, T. Wallrabenstein, B. Kolbinger, C. H. Köhne, H. A. Horst, P. Brossart, G. Held, A. Kündgen, M. Ringhoffer, K. Götze, M. Rummel, M. Gerstung, P. Campbell, J. M. Kraus, H. A. Kestler, F. Thol, M. Heuser, B. Schlegelberger, A. Ganser, L. Bullinger, R. F. Schlenk, K. Döhner, H. Döhner and G. for the German-Austrian Acute Myeloid Leukemia Study (2016). "RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features." Leukemia 30(11): 2160-2168.
  • Schlenk, R. F., M. Lübbert, A. Benner, A. Lamparter, J. Krauter, W. Herr, H. Martin, H. R. Salih, A. Kündgen, H.-A. Horst, P. Brossart, K. Götze, D. Nachbaur, M. Wattad, C.-H. Köhne, W. Fiedler, M. Bentz, G. Wulf, G. Held, B. Hertenstein, H. Salwender, V. I. Gaidzik, B. Schlegelberger, D. Weber, K. Döhner, A. Ganser, H. Döhner and G. for the German-Austrian Acute Myeloid Leukemia Study (2016). "All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study." Annals of Hematology 95(12): 1931-1942.
  • Theis, F., A. Corbacioglu, V. I. Gaidzik, P. Paschka, D. Weber, L. Bullinger, M. Heuser, A. Ganser, F. Thol, B. Schlegelberger, G. Göhring, C. H. Köhne, U. Germing, P. Brossart, H. A. Horst, D. Haase, K. Götze, M. Ringhoffer, W. Fiedler, D. Nachbaur, T. Kindler, G. Held, M. Lübbert, M. Wattad, H. R. Salih, J. Krauter, H. Döhner, R. F. Schlenk and K. Döhner (2016). "Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group." Leukemia 30(11): 2248-2250.
  • Vrhovac, R., M. Labopin, F. Ciceri, J. Finke, E. Holler, J. Tischer, B. Lioure, J. Gribben, L. Kanz, D. Blaise, P. Dreger, G. Held, R. Arnold, A. Nagler and M. Mohty (2016). "Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes." Bone Marrow Transplant 51(2): 186-193.

Älter als 2016

  • Rogacev KS, Zawada AM, Hundsdorfer J, Achenbach M, Held G, Fliser D, Heine GH. 2015. Immunosuppression and monocyte subsets. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 30: 143-53
  • Paschka P, Schlenk RF, Gaidzik VI, Herzig JK, Aulitzky T, Bullinger L, Spath D, Teleanu V, Kundgen A, Kohne CH, Brossart P, Held G, Horst HA, Ringhoffer M, Gotze K, Nachbaur D, Kindler T, Heuser M, Thol F, Ganser A, Dohner H, Dohner K. 2015. ASXL1 mutations in younger adult patients with acute myeloid leukemia: A study of the German-Austrian Acute Myeloid Leukemia Study Group. Haematologica
  • Kubuschok B, Held G, Pfreundschuh M. 2015. Management of Diffuse Large B-Cell Lymphoma (DLBCL). Cancer treatment and research 165: 271-88
  • Kittner JM, von Bialy L, Wiltink J, Thomaidis T, Gospodinov B, Rieke A, Katz F, Discher T, Rath K, Claus B, Held G, Friese G, Schappert B, Schuchmann M, Galle PR. 2015. Lack of awareness in both patients and physicians contributes to a high rate of late presentation in a South West German HIV patient cohort. Infection
  • Held G, Luescher IF, Neumann F, Papaioannou C, Schirrmann T, Sester M, Smola S, Pfreundschuh M. 2015. MHC/Peptide-Specific Interaction of the Humoral Immune System: A New Category of Antibodies. J Immunol 195: 4210-7
  • Zwick C, Held G, Auth M, Bernal-Mizrachi L, Roback JD, Sunay S, Iida S, Kuroda Y, Sakai A, Ziepert M, Ueda R, Pfreundschuh M, Preuss KD. 2014. Over one-third of African-American MGUS and multiple myeloma patients are carriers of hyperphosphorylated paratarg-7, an autosomal dominantly inherited risk factor for MGUS/MM. International journal of cancer. Journal international du cancer 135: 934-8
  • Thurner L, Stoger E, Fadle N, Klemm P, Regitz E, Kemele M, Bette B, Held G, Dauer M, Lammert F, Preuss KD, Zimmer V, Pfreundschuh M. 2014. Proinflammatory progranulin antibodies in inflammatory bowel diseases. Digestive diseases and sciences 59: 1733-42
  • Tassara M, Dohner K, Brossart P, Held G, Gotze K, Horst HA, Ringhoffer M, Kohne CH, Kremers S, Raghavachar A, Wulf G, Kirchen H, Nachbaur D, Derigs HG, Wattad M, Koller E, Brugger W, Matzdorff A, Greil R, Heil G, Paschka P, Gaidzik VI, Gottlicher M, Dohner H, Schlenk RF. 2014. Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients. Blood 123: 4027-36
  • Tappe D, Rissland J, Gabriel M, Emmerich P, Gunther S, Held G, Smola S, Schmidt-Chanasit J. 2014. First case of laboratory-confirmed Zika virus infection imported into Europe, November 2013. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 19
  • Schlenk RF, Kayser S, Bullinger L, Kobbe G, Casper J, Ringhoffer M, Held G, Brossart P, Lubbert M, Salih HR, Kindler T, Horst HA, Wulf G, Nachbaur D, Gotze K, Lamparter A, Paschka P, Gaidzik VI, Teleanu V, Spath D, Benner A, Krauter J, Ganser A, Dohner H, Dohner K. 2014. Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. Blood 124: 3441-9
  • Preuss KD, Fadle N, Regitz E, Held G, Pfreundschuh M. 2014. Inactivation of protein-phosphatase 2A causing hyperphosphorylation of autoantigenic paraprotein targets in MGUS/MM is due to an exchange of its regulatory subunits. International journal of cancer. Journal international du cancer 135: 2046-53
  • Pfreundschuh M, Poeschel V, Zeynalova S, Hanel M, Held G, Schmitz N, Viardot A, Dreyling MH, Hallek M, Mueller C, Wiesen MH, Witzens-Harig M, Truemper L, Keller U, Rixecker T, Zwick C, Murawski N. 2014. Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 32: 4127-33
  • Pfreundschuh M, Muller C, Zeynalova S, Kuhnt E, Wiesen MH, Held G, Rixecker T, Poeschel V, Zwick C, Reiser M, Schmitz N, Murawski N. 2014. Suboptimal dosing of rituximab in male and female patients with DLBCL. Blood 123: 640-6
  • Murawski N, Pfreundschuh M, Zeynalova S, Poeschel V, Hanel M, Held G, Schmitz N, Viardot A, Schmidt C, Hallek M, Witzens-Harig M, Trumper L, Rixecker T, Zwick C. 2014. Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 25: 1800-6
  • Murawski N, Held G, Ziepert M, Kempf B, Viardot A, Hanel M, Witzens-Harig M, Mahlberg R, Rube C, Fleckenstein J, Zwick C, Glass B, Schmitz N, Zeynalova S, Pfreundschuh M. 2014. The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas. Blood 124: 720-8
  • Hohloch K, Zeynalova S, Held G, Ziepert M, Loeffler M, Wulf G, Schmitz N, Pfreundschuh M, Trumper L. 2014. Excellent outcome of young adults with aggressive non-Hodgkin lymphomas treated with CHOP-like regimens. Leukemia 28: 2260-3
  • Held G, Murawski N, Ziepert M, Fleckenstein J, Poschel V, Zwick C, Bittenbring J, Hanel M, Wilhelm S, Schubert J, Schmitz N, Loffler M, Rube C, Pfreundschuh M. 2014. Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 32: 1112-8
  • Bittenbring JT, Neumann F, Altmann B, Achenbach M, Reichrath J, Ziepert M, Geisel J, Regitz E, Held G, Pfreundschuh M. 2014. Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 32: 3242-8
  • Achenbach M, Bittenbring JT, Ziepert M, Regitz E, Ott G, Rosenwald A, Pfreundschuh M, Altmann B, Held G. 2014. Elevated serum free light chains do not predict outcome of elderly patients with aggressive CD20(+) B-cell lymphomas. British journal of haematology 167: 430-4
  • Schuberth PC, Jakka G, Jensen SM, Wadle A, Gautschi F, Haley D, Haile S, Mischo A, Held G, Thiel M, Tinguely M, Bifulco CB, Fox BA, Renner C, Petrausch U. 2013. Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma. Gene therapy 20: 386-95
  • Schlenk RF, Taskesen E, van Norden Y, Krauter J, Ganser A, Bullinger L, Gaidzik VI, Paschka P, Corbacioglu A, Gohring G, Kundgen A, Held G, Gotze K, Vellenga E, Kuball J, Schanz U, Passweg J, Pabst T, Maertens J, Ossenkoppele GJ, Delwel R, Dohner H, Cornelissen JJ, Dohner K, Lowenberg B. 2013. The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. Blood
  • Paschka P, Du J, Schlenk RF, Gaidzik VI, Bullinger L, Corbacioglu A, Spath D, Kayser S, Schlegelberger B, Krauter J, Ganser A, Kohne CH, Held G, von Lilienfeld-Toal M, Kirchen H, Rummel M, Gotze K, Horst HA, Ringhoffer M, Lubbert M, Wattad M, Salih HR, Kundgen A, Dohner H, Dohner K. 2013. Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG). Blood 121: 170-7
  • Neumann F, Kaddu-Mulindwa D, Widmann T, Preuss KD, Held G, Zwick C, Roemer K, Pfreundschuh M, Kubuschok B. 2013. EBV-transformed lymphoblastoid cell lines as vaccines against cancer testis antigen-positive tumors. Cancer immunology, immunotherapy: CII 62: 1211-22
  • Jakka G, Schuberth PC, Thiel M, Held G, Stenner F, Van Den Broek M, Renner C, Mischo A, Petrausch U. 2013. Antigen-specific in vitro expansion of functional redirected NY-ESO-1-specific human CD8+ T-cells in a cell-free system. Anticancer research 33: 4189-201
  • Held G, Zeynalova S, Murawski N, Ziepert M, Kempf B, Viardot A, Dreyling M, Hallek M, Witzens-Harig M, Fleckenstein J, Rube C, Zwick C, Glass B, Schmitz N, Pfreundschuh M. 2013. Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 31: 4115-22
  • Almunia C, Bretaudeau M, Held G, Babon A, Marchetti C, Castelli FA, Menez A, Maillere B, Gillet D. 2013. Bee Venom Phospholipase A2, a Good "Chauffeur" for Delivering Tumor Antigen to the MHC I and MHC II Peptide-Loading Compartments of the Dendritic Cells: The Case of NY-ESO-1. PloS one 8: e67645
  • Alchi B, Jayne D, Labopin M, Demin A, Sergeevicheva V, Alexander T, Gualandi F, Gruhn B, Ouyang J, Rzepecki P, Held G, Sampol A, Voswinkel J, Ljungman P, Fassas A, Badoglio M, Saccardi R, Farge D. 2013. Autologous haematopoietic stem cell transplantation for systemic lupus erythematosus: data from the European Group for Blood and Marrow Transplantation registry. Lupus 22: 245-53
  • Rucker FG, Schlenk RF, Bullinger L, Kayser S, Teleanu V, Kett H, Habdank M, Kugler CM, Holzmann K, Gaidzik VI, Paschka P, Held G, von Lilienfeld-Toal M, Lubbert M, Frohling S, Zenz T, Krauter J, Schlegelberger B, Ganser A, Lichter P, Dohner K, Dohner H. 2012. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood 119: 2114-21
  • Muller C, Murawski N, Wiesen MH, Held G, Poeschel V, Zeynalova S, Wenger M, Nickenig C, Peter N, Lengfelder E, Metzner B, Rixecker T, Zwick C, Pfreundschuh M, Reiser M. 2012. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood 119: 3276-84
  • Kubuschok B, Pfreundschuh M, Breit R, Hartmann F, Sester M, Gartner B, Konig J, Murawski N, Held G, Zwick C, Neumann F. 2012. Mutated Ras-transfected, EBV-transformed lymphoblastoid cell lines as a model tumor vaccine for boosting T-cell responses against pancreatic cancer: a pilot trial. Human gene therapy 23: 1224-36
  • Kayser S, Zucknick M, Dohner K, Krauter J, Kohne CH, Horst HA, Held G, von Lilienfeld-Toal M, Wilhelm S, Rummel M, Germing U, Gotze K, Nachbaur D, Schlegelberger B, Gohring G, Spath D, Morlok C, Teleanu V, Ganser A, Dohner H, Schlenk RF. 2012. Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies. Blood 119: 551-8
  • Gaidzik VI, Paschka P, Spath D, Habdank M, Kohne CH, Germing U, von Lilienfeld-Toal M, Held G, Horst HA, Haase D, Bentz M, Gotze K, Dohner H, Schlenk RF, Bullinger L, Dohner K. 2012. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 30: 1350-7
  • Preuss KD, Pfreundschuh M, Fadle N, Regitz E, Raudies S, Murwaski N, Ahlgrimm M, Bittenbring J, Klotz M, Schafer KH, Held G, Neumann F, Grass S. 2011. Hyperphosphorylation of autoantigenic targets of paraproteins is due to inactivation of PP2A. Blood 118: 3340-6
  • Meissner M, Obmann VC, Hoschke M, Link S, Jung M, Held G, Philipp SE, Zimmermann R, Flockerzi V. 2011. Lessons of Studying TRP Channels with Antibodies. In TRP Channels, ed. MX Zhu. Boca Raton (FL)
  • Kronke J, Schlenk RF, Jensen KO, Tschurtz F, Corbacioglu A, Gaidzik VI, Paschka P, Onken S, Eiwen K, Habdank M, Spath D, Lubbert M, Wattad M, Kindler T, Salih HR, Held G, Nachbaur D, von Lilienfeld-Toal M, Germing U, Haase D, Mergenthaler HG, Krauter J, Ganser A, Gohring G, Schlegelberger B, Dohner H, Dohner K. 2011. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 29: 2709-16
  • Kayser S, Dohner K, Krauter J, Kohne CH, Horst HA, Held G, von Lilienfeld-Toal M, Wilhelm S, Kundgen A, Gotze K, Rummel M, Nachbaur D, Schlegelberger B, Gohring G, Spath D, Morlok C, Zucknick M, Ganser A, Dohner H, Schlenk RF. 2011. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 117: 2137-45
  • Wadle A, Mischo A, Strahl S, Nishikawa H, Held G, Neumann F, Wullner B, Fischer E, Kleber S, Karbach J, Jager E, Shiku H, Odunsi K, Shrikant PA, Knuth A, Cerundolo V, Renner C. 2010. NY-ESO-1 protein glycosylated by yeast induces enhanced immune responses. Yeast 27: 919-31
  • Zwick C, Preuss KD, Kubuschok B, Held G, Ahlgrimm M, Bittenbring J, Schubert J, Neumann F, Pfreundschuh M. 2009. Analysis of the antibody repertoire of patients with mantle cell lymphoma directed against mantle cell lymphoma-associated antigens. Annals of hematology 88: 999-1003
  • Zwick C, Held G, Hammermeister V, Alahmad A, Kubuschok B, Bittenbring J, Ahlgrimm M, Neumann F, Preuss KD, Pfreundschuh M. 2009. Spontaneous high-titered IgG antibody responses against BCL-2 in patients with aggressive lymphomas. Journal of cancer research and clinical oncology 135: 1207-13
  • Stewart-Jones G, Wadle A, Hombach A, Shenderov E, Held G, Fischer E, Kleber S, Nuber N, Stenner-Liewen F, Bauer S, McMichael A, Knuth A, Abken H, Hombach AA, Cerundolo V, Jones EY, Renner C. 2009. Rational development of high-affinity T-cell receptor-like antibodies. Proceedings of the National Academy of Sciences of the United States of America 106: 5784-8
  • Neumann F, Sturm C, Hulsmeyer M, Dauth N, Guillaume P, Luescher IF, Pfreundschuh M, Held G. 2009. Fab antibodies capable of blocking T cells by competitive binding have the identical specificity but a higher affinity to the MHC-peptide-complex than the T cell receptor. Immunology letters 125: 86-92
  • Held G, Pfreundschuh M. 2009. Hematology: germinal center or nongerminal center DLBCL? Nature reviews. Clinical oncology 6: 188-90
  • Voswinkel J, Kerkdijk AJ, Mueller A, Assmann G, Pfreundschuh M, Held G. 2008. A novel system to test for specificity of B cell receptors from tissue of Wegener's granulomatosis patients. Clinical and experimental rheumatology 26: S90-6
  • 44. Voswinkel J, Assmann G, Held G, Pitann S, Gross WL, Holl-Ulrich K, Herlyn K, Mueller A. 2008. Single cell analysis of B lymphocytes from Wegener's granulomatosis: B cell receptors display affinity maturation within the granulomatous lesions. Clinical and experimental immunology 154: 339-45
  • Held G, Schubert J, Pfreundschuh M. 2008. [Treatment of hematological malignancies with monoclonal antibodies]. Der Internist 49: 929-30, 32-4, 36-7
  • Held G, Neumann F, Sturm C, Kaestner L, Dauth N, de Bruijn DR, Renner C, Lipp P, Pfreundschuh M. 2008. Differential presentation of tumor antigen-derived epitopes by MHC-class I and antigen-positive tumor cells. International journal of cancer. Journal international du cancer 123: 1841-7
  • Preuss KD, Held G, Kubuschok B, Hung CZ, Malatsidze N, Wagner M, Pfreundschuh M. 2007. Identification of antigenic targets of paraproteins by expression cloning does not support a causal role of chronic antigenic stimulation in the pathogenesis of multiple myeloma and MGUS. International journal of cancer. Journal international du cancer 121: 459-61
  • Held G, Wadle A, Dauth N, Stewart-Jones G, Sturm C, Thiel M, Zwick C, Dieckmann D, Schuler G, Hoogenboom HR, Levy F, Cerundolo V, Pfreundschuh M, Renner C. 2007. MHC-peptide-specific antibodies reveal inefficient presentation of an HLA-A*0201-restricted, Melan-A-derived peptide after active intracellular processing. European journal of immunology 37: 2008-17
  • Wadle A, Held G, Neumann F, Kleber S, Wuellner B, Asemissen AM, Kubuschok B, Scheibenbogen C, Breinig T, Meyerhans A, Renner C. 2006. Cross-presentation of HLA class I epitopes from influenza matrix protein produced in Saccharomyces cerevisiae. Vaccine 24: 6272-81
  • Held G, Schubert J, Reiser M, Pfreundschuh M. 2006. Dose-intensified treatment of advanced-stage diffuse large B-cell lymphomas. Seminars in hematology 43: 221-9
  • Held G, Poschel V, Pfreundschuh M. 2006. Rituximab for the treatment of diffuse large B-cell lymphomas. Expert review of anticancer therapy 6: 1175-86
  • Hulsmeyer M, Chames P, Hillig RC, Stanfield RL, Held G, Coulie PG, Alings C, Wille G, Saenger W, Uchanska-Ziegler B, Hoogenboom HR, Ziegler A. 2005. A major histocompatibility complex-peptide-restricted antibody and t cell receptor molecules recognize their target by distinct binding modes: crystal structure of human leukocyte antigen (HLA)-A1-MAGE-A1 in complex with FAB-HYB3. The Journal of biological chemistry 280: 2972-80
  • Chen JL, Stewart-Jones G, Bossi G, Lissin NM, Wooldridge L, Choi EM, Held G, Dunbar PR, Esnouf RM, Sami M, Boulter JM, Rizkallah P, Renner C, Sewell A, van der Merwe PA, Jakobsen BK, Griffiths G, Jones EY, Cerundolo V. 2005. Structural and kinetic basis for heightened immunogenicity of T cell vaccines. The Journal of experimental medicine 201: 1243-55
  • Held G, Matsuo M, Epel M, Gnjatic S, Ritter G, Lee SY, Tai TY, Cohen CJ, Old LJ, Pfreundschuh M, Reiter Y, Hoogenboom HR, Renner C. 2004. Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments. European journal of immunology 34: 2919-29
  • Hartmann F, Renner C, Jung W, da Costa L, Tembrink S, Held G, Sek A, Konig J, Bauer S, Kloft M, Pfreundschuh M. 2001. Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines. Clinical cancer research: an official journal of the American Association for Cancer Research 7: 1873-81
  • Bauer S, Renner C, Juwana JP, Held G, Ohnesorge S, Gerlach K, Pfreundschuh M. 1999. Immunotherapy of human tumors with T-cell-activating bispecific antibodies: stimulation of cytotoxic pathways in vivo. Cancer research 59: 1961-5
  • Renner C, Pfitzenmeier JP, Gerlach K, Held G, Ohnesorge S, Sahin U, Bauer S, Pfreundschuh M. 1997. RP1, a new member of the adenomatous polyposis coli-binding EB1-like gene family, is differentially expressed in activated T cells. Journal of immunology 159: 1276-83
  • Renner C, Held G, Ohnesorge S, Bauer S, Gerlach K, Pfitzenmeier JP, Pfreundschuh M. 1997. Role of perforin, granzymes and the proliferative state of the target cells in apoptosis and necrosis mediated by bispecific-antibody-activated cytotoxic T cells. Cancer immunology, immunotherapy : CII 44: 70-6
  • Renner C, Held G, Ohnesorge S, Bauer S, Gerlach K, Pfitzenmeier JP, Pfreundschuh M. 1997. Role of naive and memory T cells in tumor cell lysis mediated by bi-specific antibodies. Immunobiology 197: 122-32
  • Renner C, Ohnesorge S, Held G, Bauer S, Jung W, Pfitzenmeier JP, Pfreundschuh M. 1996. T cells from patients with Hodgkin's disease have a defective T-cell receptor zeta chain expression that is reversible by T-cell stimulation with CD3 and CD28. Blood 88: 236-41
  • Renner C, Bauer S, Sahin U, Jung W, van Lier R, Jacobs G, Held G, Pfreundschuh M. 1996. Cure of disseminated xenografted human Hodgkin's tumors by bispecific monoclonal antibodies and human T cells: the role of human T-cell subsets in a preclinical model. Blood 87: 2930-7